evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

6 questions · 6 findings · 3 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 16.7%Low 2 · 33.3%Moderate 3 · 50%High 0 · 0%

Standard‐dose VKA plus single antiplatelet agent vs vitamin K antagonist (VKA)

Total mortalitya · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes all‐cause mortalitya compared with standard‐dose VKA (very low certainty).

1 finding from 1 review

Anticoagulant drugs: VKA high dose vs vitamin K antagonist (VKA)

Total mortalitya · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

High‐dose VKA showed no clear difference in all‐cause mortalitya compared with standard‐dose VKA (low certainty).

1 finding from 1 review

NOAC (rivaroxaban) vs vitamin K antagonist (VKA)

Total mortalitya · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

NOAC (rivaroxaban) showed no clear difference in all‐cause mortalitya compared with standard‐dose VKA (moderate certainty).

1 finding from 1 review

Intervention not reported

28‐day all‐cause mortality · hospitalised adults with COVID‐19 (moderate to severe disease)

The intervention probably leads to lower 28‐day all‐cause mortality (moderate certainty).

1 finding from 1 review

Intervention not reported

All‐cause mortality at day 45 · non‐hospitalised adults with mild COVID‐19

The intervention showed no clear difference in all‐cause mortality at day 45 (low certainty).

1 finding from 1 review